• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ellomay Capital Announces Changes in its Principal Shareholders and Board Composition

    3/4/26 4:32:10 PM ET
    $ELLO
    $PLX
    Electric Utilities: Central
    Utilities
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ELLO alert in real time by email

    Tel-Aviv, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- Ellomay Capital Ltd. (NYSE American; TASE: ELLO) ("Ellomay" or the "Company"), a renewable energy and power generator and developer of renewable energy and power projects in Europe, Israel and the USA, today announced that its principal shareholders, S. Nechama Investments (2008) Ltd., Kanir Joint Investments (2005) LP and Ms. Anat Raphael, who together currently hold approximately 45.9% of the Company's outstanding share capital, informed it that they have completed the sale of all of the Company's ordinary shares held by them to O.Y. Nofar Energy Ltd. ("Nofar"), a public company listed on the Tel Aviv Stock Exchange Ltd. (TASE: NOFR).

    In connection with the sale of the shares, two members of the Company's Board of Directors, Ms. Anita Leviant and Mr. Ehud Gil, resigned from the Board effective immediately and the Chairman of the Board of Directors, Mr. Ben Sheizaf, informed the Company that he will resign from the Board of Directors effective 30 days from the consummation of the sale of the shares. The Board of Directors unanimously appointed two new independent non-executive directors to fill the vacancies created, Ms. Odelya Ohayon and Mr. Gilad Mamlok. Mr. Mamlok was appointed as a member of the Audit Committee and the Compensation Committee, replacing Ms. Leviant.

    Odelya Ohayon is a strategic leader and business development expert with over 15 years of executive experience. She currently provides high-level strategic advisory to CEOs and Boards, focusing on business strategy and market-leading innovation. Previously, she served as VP of Marketing at Samsung Electronics Israel, where she was a member of the Executive Management Team and managed an annual turnover of NIS 1.5 billion. Her prior leadership roles include VP of Marketing and Business Development at Solgar & Supherb and Marketing Manager at Partner Communications, where she managed portfolios exceeding NIS 2 billion. Ms. Ohayon is a lecturer in marketing and entrepreneurship at the College of Management and Ariel University. She holds a B.A. in Business Administration from Ben-Gurion University and an M.B.A. from the Academic Studies Center.

    Gilad Mamlok serves as the Chief Financial Officer of Protalix BioTherapeutics, Inc. (NYSE:PLX) since August 2025. Mr. Mamlok is a seasoned financial executive with three decades of experience in healthcare and technology companies. He has an extensive background in capital markets transactions, mergers and acquisitions, business development and investor relations as well as in corporate governance matters. Prior to his role in Protalix, he served as the Chief Financial Officer of TytoCare Ltd., a privately-held company in the remote healthcare space. Prior to his role at TytoCare, Mr. Mamlok served as the Chief Financial Officer of Sol-Gel Technologies Ltd. In this role, he was responsible for an initial public offering and other capital markets transactions, as well as in-licensing and out-licensing transactions. Prior to his role at Sol-Gel, he served in other medical device companies, including Given Imaging which was acquired by Covidien plc in 2014. Mr. Mamlok holds a BA in Economics, magna cum laude, and a Master's degree in Business/Managerial Economics, both from the Tel Aviv University.

    Ran Fridrich, CEO and Board member of Ellomay commented: "On behalf of the Company and the Board, I would like to express our sincere gratitude to Anita and Ehud for their dedicated service and meaningful contributions during their tenure. We thank them for their commitment and wish them continued success in their future endeavors. We are pleased to welcome Odelya and Gilad to the Board. We are confident that their experience, insight and leadership will be valuable assets to the Company. We look forward to working closely with them and are certain they will play an important role in guiding the Company toward continued growth and success."

    About Ellomay Capital Ltd.

    Ellomay is an Israeli based company whose shares are registered with the NYSE American and with the Tel Aviv Stock Exchange under the trading symbol "ELLO". Since 2009, Ellomay Capital focuses its business in the renewable energy and power sectors in Europe, USA and Israel.

    To date, Ellomay has evaluated numerous opportunities and invested significant funds in the renewable, clean energy and natural resources industries in Israel, Italy, Spain, the Netherlands and Texas, USA, including:

    • Approximately 335.9 MW of operating solar power plants in Spain (including a 300 MW solar plant in owned by Talasol, which is 51% owned by the Company) and 51% of approximately 38 MW of operating solar power plants in Italy;
    • 16.875% indirect interest in Dorad Energy Ltd., which owns and operates one of Israel's largest private power plants with production capacity of approximately 850 MW;
    • Groen Gas Goor B.V., Groen Gas Oude-Tonge B.V. and Groen Gas Gelderland B.V., project companies operating anaerobic digestion plants in the Netherlands, with a green gas production capacity of approximately 3 million, 3.8 million and 9.5 million Nm3 per year, respectively;
    • 83.333% of Ellomay Pumped Storage (2014) Ltd., which is involved in a project to construct a 156 MW pumped storage hydro power plant in the Manara Cliff, Israel;
    • 51% of solar projects in Italy with an aggregate capacity of 160 MW that are under construction;
    • Solar projects in Italy with an aggregate capacity of 210 MW that have reached "ready to build" status; and
    • Solar projects in the Dallas Metropolitan area, Texas, USA with an aggregate capacity of approximately 38 MW that are connected to the grid, 11 MW that are awaiting connection to the grid and 14 MW that are under construction.

    For more information about Ellomay, visit http://www.ellomay.com.

    Information Relating to Forward-Looking Statements

    This press release contains forward-looking statements that involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company's management. All statements, other than statements of historical facts, included in this press release regarding the Company's plans and objectives, expectations and assumptions of management are forward-looking statements. The use of certain words, including the words "estimate," "project," "intend," "expect," "believe" and similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the Company's forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by the Company's forward-looking statements, including changes in electricity prices and demand, regulatory changes increases in interest rates and inflation, changes in the supply and prices of resources required for the operation of the Company's facilities (such as waste and natural gas) and in the price of oil, the impact of the war and hostilities in Israel and Gaza and between Israel and Iran, the outcome of legal proceedings in connection with Dorad Energy Ltd., technical and other disruptions in the operations or construction of the power plants owned by the Company, inability to obtain the financing required for the development and construction of projects, inability to advance the expansion of Dorad, increases in interest rates and inflation, changes in exchange rates, delays in development, construction, or commencement of operation of the projects under development, failure to obtain permits - whether within the set time frame or at all, climate change, the impact of the continued military conflict between Russia and Ukraine, and general market, political and economic conditions in the countries in which the Company operates, including Israel, Spain, Italy and the United States. These and other risks and uncertainties associated with the Company's business are described in greater detail in the filings the Company makes from time to time with Securities and Exchange Commission, including its Annual Report on Form 20-F. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

    Contact:

    Kalia Rubenbach (Weintraub)

    CFO

    Tel: +972 (3) 797-1111

    Email: [email protected]



    Primary Logo

    Get the next $ELLO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELLO
    $PLX

    CompanyDatePrice TargetRatingAnalyst
    More analyst ratings

    $ELLO
    $PLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ellomay Capital Announces Changes in its Principal Shareholders and Board Composition

    Tel-Aviv, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- Ellomay Capital Ltd. (NYSE American; TASE: ELLO) ("Ellomay" or the "Company"), a renewable energy and power generator and developer of renewable energy and power projects in Europe, Israel and the USA, today announced that its principal shareholders, S. Nechama Investments (2008) Ltd., Kanir Joint Investments (2005) LP and Ms. Anat Raphael, who together currently hold approximately 45.9% of the Company's outstanding share capital, informed it that they have completed the sale of all of the Company's ordinary shares held by them to O.Y. Nofar Energy Ltd. ("Nofar"), a public company listed on the Tel Aviv Stock Exchange Ltd. (TASE: NOFR).

    3/4/26 4:32:10 PM ET
    $ELLO
    $PLX
    Electric Utilities: Central
    Utilities
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU

    Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2026 If approved by the EC, this dosing regimen would reduce the burden to eligible adult patients, their families and the broader healthcare system due to the current requirement to visit infusion centres or have home infusions every-2-weeks for treatment PARMA, Italy and CARMIEL, Israel, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, and Protali

    1/30/26 9:47:42 AM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

    Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2026 If approved by the EC, this dosing regimen would reduce the burden to eligible patients, their families, and the broader healthcare system due to the current requirement to visit infusion centres every two weeks for treatment This dosing regimen for Elfabrio is not approved in the U.S. In the U.S., the approved dosing regimen remains 1 mg/kg every 2 weeks. Please consult with your healthcare provider PARMA, Italy and CARMIEL, Israel, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Chiesi Global Rare

    1/30/26 9:47:43 AM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELLO
    $PLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Protalix BioTherapeutics with a new price target

    HC Wainwright & Co. reiterated coverage of Protalix BioTherapeutics with a rating of Buy and set a new price target of $7.00 from $11.00 previously

    5/3/21 7:36:38 AM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELLO
    $PLX
    SEC Filings

    View All

    SEC Form 6-K filed by Ellomay Capital Ltd

    6-K - Ellomay Capital Ltd. (0000946394) (Filer)

    3/4/26 4:33:55 PM ET
    $ELLO
    Electric Utilities: Central
    Utilities

    SEC Form 6-K filed by Ellomay Capital Ltd

    6-K - Ellomay Capital Ltd. (0000946394) (Filer)

    2/12/26 4:15:30 PM ET
    $ELLO
    Electric Utilities: Central
    Utilities

    Protalix BioTherapeutics Inc. (DE) filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)

    2/11/26 5:10:47 PM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELLO
    $PLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT AND CEO Bashan Dror bought $101,360 worth of shares (56,000 units at $1.81), increasing direct ownership by 42% to 188,516 units (SEC Form 4)

    4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)

    12/23/25 7:25:58 AM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Bar-Shalev Amos sold $314 worth of shares (168 units at $1.87), closing all direct ownership in the company (SEC Form 4)

    4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)

    11/19/25 4:34:55 PM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Forster Eliot was granted 7,500 shares (SEC Form 4)

    4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)

    9/4/25 5:00:24 PM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELLO
    $PLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT AND CEO Bashan Dror bought $101,360 worth of shares (56,000 units at $1.81), increasing direct ownership by 42% to 188,516 units (SEC Form 4)

    4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)

    12/23/25 7:25:58 AM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Schwartz Aharon bought $205,884 worth of shares (129,000 units at $1.60), increasing direct ownership by 74% to 303,000 units (SEC Form 4)

    4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)

    8/12/25 4:30:07 PM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bashan Dror bought $90,484 worth of shares (64,516 units at $1.40), increasing direct ownership by 95% to 132,516 units (SEC Form 4)

    4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)

    10/20/23 6:50:07 AM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELLO
    $PLX
    Financials

    Live finance-specific insights

    View All

    Ellomay Capital Reports Publication of Financial Statements of Dorad Energy Ltd. as of and for the Three and Nine Months Ended September 30, 2025

    TEL AVIV, Israel, Nov. 30, 2025 (GLOBE NEWSWIRE) -- Ellomay Capital Ltd. (NYSE American; TASE: ELLO) ("Ellomay" or the "Company"), a renewable energy and power generator and developer of renewable energy and power projects in Europe, Israel and USA, today reported the publication in Israel of financial statements as of and for the three and nine months ended September 30, 2025 of Dorad Energy Ltd. ("Dorad"), in which Ellomay currently indirectly holds approximately 16.9% through its indirect 50% ownership of Ellomay Luzon Energy Infrastructures Ltd. ("Ellomay Luzon Energy"). On November 30, 2025, Amos Luzon Entrepreneurship and Energy Group Ltd. (the "Luzon Group"), an Israeli public co

    11/30/25 12:24:58 PM ET
    $ELLO
    Electric Utilities: Central
    Utilities

    Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results

    Company to host conference call and webcast today at 8:00 a.m. EST CARMIEL, Israel, Nov. 13, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended September 30, 2025, and provided a financial and business update. "We are pleased to report total revenues of $43.6 million for the first nine months of

    11/13/25 6:50:00 AM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025

    Company to host conference call and webcast at 8:00 a.m. EST CARMIEL, Israel, Nov. 6, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended September 30, 2025 and provide a financial and business update on November 13, 2025. Management will host a conference call to discuss the financial results and provide an update on recent developments. Conference Call Details:Date: Thursday, Novembe

    11/6/25 6:50:00 AM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELLO
    $PLX
    Leadership Updates

    Live Leadership Updates

    View All

    Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement

    Partnership combines Protalix's rare disease and biologics expertise with Secarna's AI–powered OligoCreator® platform to jointly develop pharmaceutical candidates for rare renal indications Protalix is granted an exclusive option to license any active compounds derived from the research for potential clinical development and commercialization CARMIEL, Israel and MARTINSRIED, Germany, Dec. 17, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs, and Secarna Pharmaceuticals GmbH & Co. KG, a company re

    12/17/25 6:50:00 AM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Levicept Appoints Eliot Forster as CEO

    Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur

    11/30/23 4:00:00 AM ET
    $IMCR
    $IMTX
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

    Appointment effective as of September 14, 2023;Zeev Bronfeld to retire from the Board of Directors CARMIEL, Israel, Sept. 12, 2023 /PRNewswire / Protalix BioTherapeutics, Inc. (NYSE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that the Company's Board of Directors has appointed Eliot Richard Forster, Ph.D. to serve on the Board of Directors as its Chairman, effective as of September 14, 2023. In

    9/12/23 6:50:00 AM ET
    $IMTX
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELLO
    $PLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ellomay Capital Ltd

    SC 13G/A - Ellomay Capital Ltd. (0000946394) (Subject)

    11/14/24 6:27:22 AM ET
    $ELLO
    Electric Utilities: Central
    Utilities

    Amendment: SEC Form SC 13G/A filed by Protalix BioTherapeutics Inc. (DE)

    SC 13G/A - Protalix BioTherapeutics, Inc. (0001006281) (Subject)

    10/25/24 4:23:48 PM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Ellomay Capital Ltd (Amendment)

    SC 13G/A - Ellomay Capital Ltd. (0000946394) (Subject)

    2/14/24 3:06:28 PM ET
    $ELLO
    Electric Utilities: Central
    Utilities